We believe there is a clear opportunity to generate significant value for our shareholders over the next 12 months, given recent progress with both our clinical and preclinical programmes.
Dr Tim Mitchell, chief executive
Sareum Holdings PLC‘s (LON:SAR) most advanced programme was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase II clinical trials conducted by licence partner Sierra Oncology.
The drug developer has two other preclinical discoveries – focused on autoimmune disease and cancer.
This is a checkpoint kinase 1 inhibitor, a type of drug that controls a cancer cell’s response to DNA damage
It is currently undergoing two Phase II clinical trials in patients with advanced cancer – one as a monotherapy and another in combination with low-dose gemcitabine, which is one of the most commonly commonly-prescribed chemotherapies.
Preliminary efficacy data from a phase I/II clinical trial carried out by Vancouver-based Sierra Oncology, which licensed the drug candidate in a deal worth up to US$328.5mln plus royalties, was encouraging.
Most eye-catching among the headlines was the impact SRA737 had in harness with gemcitabine in patients with anogenital cancer, where the response rate was 30%.
New research in March also highlighted the therapeutic potential of SRA737 in a new drug combination targeting lung and colorectal cancers published in Cancer Research, a leading peer-reviewed journal
What else is in the pipeline
Sareum’s SDC-1801 and SDC-1802 drug candidates, which are respectively being developed to treat autoimmune diseases and cancers are progressing through pre-clinical development and should undergo first in-human clinical trials in 2020.
Both Sareum programmes have progressed well since being chosen in September 2018 for further development.
Data items arising from some of the development work are being prepared for submission to a peer-reviewed publication and a conference presentation.
In March, it entered into an agreement with a China-based speciality pharmaceutical company to develop, manufacture and commercialise certain small molecule inhibitors of FLT3+Aurora kinases including Sareum’s lead candidate SAR-20293.
In June, the company raised £718,500 before expenses via a placing of shares at 0.6p each with the new funds used to explore the potential benefit of its TYK2/JAK1 inhibitors against coronavirus (COVID-19).
A separate fundraiser overseen by PrimaryBid will offer private investors new shares in the company on the same terms.
As at March 31, 2020, Sareum had cash of £980,000. It expects to receive a research and development tax credit next January of £150,000.
What the boss says: Tim Mitchell, CEO (June)
WSareum continues to engage with interested parties regarding the further development and potential commercialisation” of TYK2/JAK1 drugs SDC-1801 and SDC-1802.
“We are targeting the completion of at least one preclinical study in the fourth quarter and are developing our plans for the initial clinical trials with both compounds,
- Commercial licences for the late pre-clinical or early clinical stages of SDC 1801/1802
- Sierra Oncology raises funds for development of SRA737
- Raised £7i8,000 in June